HRT Financial’s Legend Biotech LEGN Stock Holding History

HRT Financial’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$693K	Buy	+24,000	New	+$647K	﹤0.01%	2403

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

HRT Financial's LEGN Position: Q2 2024 in Review

HRT Financial sold out of Legend Biotech (LEGN) in Q2 2024, closing a stake of 9,959 shares — an estimated $558K sold.

HRT Financial first reported a position in LEGN in Q1 2024 and held it in 1 quarter. The position peaked at $558K in Q1 2024. 181 funds tracked by Wall St. Rank hold LEGN as of Q2 2024.

HRT Financial reported no remaining Legend Biotech position as of Q2 2024 after selling out during the quarter.
HRT Financial sold 9,959 Legend Biotech shares in Q2 2024, an estimated $558K.
HRT Financial first reported a position in Legend Biotech in Q1 2024 and held it in 1 quarter.
HRT Financial's Legend Biotech position peaked at $558K in Q1 2024.
181 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2024.

Based on HRT Financial's 13F filing for Q2 2024, filed 12 Aug 2024.